Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

Open Access 01-12-2020 | Hashimoto Thyroiditis | Case report

Basedow’s disease with associated features of Hashimoto’s thyroiditis based on histopathological findings

Authors: Megumi Horiya, Takatoshi Anno, Fumiko Kawasaki, Yuichiro Iwamoto, Shintaro Irie, Yasumasa Monobe, Koichi Tomoda, Kohei Kaku, Shuhei Nakanishi, Hideaki Kaneto

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Basedow’s disease and Hashimoto’s thyroiditis are autoimmune thyroid disorders and usually diagnosed with elevation of serum autoimmune antibodies. Thyrotropin receptor antibodies (TRAb) and/or thyroid-stimulating antibody (TSAb) are usually used for diagnosis of Basedow’s disease, and thyroid peroxidase antibodies (TPOAb) and/or thyroglobulin antibodies (TgAb) are for diagnosis of Hashimoto’s thyroiditis. However, it is difficult to diagnose a subject as Basedow’s disease with associated features of Hashimoto’s thyroiditis only with elevation of such autoimmune antibodies.

Case presentation

A 44-year-old woman with 5-year history of Basedow’s disease underwent a total thyroidectomy. She did not have a goiter. TRAb, TSAb, TPOAg and TgAb were all positive before a total thyroidectomy. In histopathological macroscopic examination, diffuse hyperplasia of the thyroid gland was observed. Furthermore, in histopathological microscopic examination, both characteristics of Basedow’s disease and Hashimoto’s thyroiditis were observed. After a total thyroidectomy, titers of all thyroid-associated autoimmune antibodies were markedly reduced.

Conclusion

Herein, we report a subject with Basedow’s disease without a goiter whose TPOAb and TgAb were relatively high at the onset of Basedow’s disease. In addition, interestingly, the histopathological findings of this subject showed direct signs of Basedow’s disease and Hashimoto’s thyroiditis in the same thyroid gland. Considering from such findings, she seemed to have Basedow’s disease with associated features of Hashimoto’s thyroiditis. In conclusion, we should bear in mind the possibility of Basedow’s disease with associated features of Hashimoto’s thyroiditis in subjects with Basedow’s disease, particularly when TPOAb and TgAb as well as TRAb and TSAb are positive.
Literature
1.
go back to reference Gauna A, Segura G, Sartorio G, Soto R, Segal-Eiras A. Immunological aspects of Graves' disease patients in different clinical stages. J Endocrinol Investig. 1989;12:671–7.CrossRef Gauna A, Segura G, Sartorio G, Soto R, Segal-Eiras A. Immunological aspects of Graves' disease patients in different clinical stages. J Endocrinol Investig. 1989;12:671–7.CrossRef
2.
go back to reference Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, et al. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Clin Endocrinol. 1995;43:551–6.CrossRef Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, et al. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Clin Endocrinol. 1995;43:551–6.CrossRef
3.
go back to reference Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348:2646–55.CrossRef Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348:2646–55.CrossRef
4.
go back to reference Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996;335:99–107.CrossRef Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996;335:99–107.CrossRef
5.
go back to reference Takamatsu J, Yoshida S, Yokozawa T, Hirai K, Kuma K, Ohsawa N, et al. Correlation of antithyroglobulin and antithyroid-peroxidase antibody profiles with clinical and ultrasound characteristics of chronic thyroiditis. Thyroid. 1998;8:1101–6.CrossRef Takamatsu J, Yoshida S, Yokozawa T, Hirai K, Kuma K, Ohsawa N, et al. Correlation of antithyroglobulin and antithyroid-peroxidase antibody profiles with clinical and ultrasound characteristics of chronic thyroiditis. Thyroid. 1998;8:1101–6.CrossRef
6.
go back to reference Zeitlin AA, Simmonds MJ, Gough SC. Genetic developments in autoimmune thyroid disease: an evolutionary process. Clin Endocrinol. 2008;68:671–82.CrossRef Zeitlin AA, Simmonds MJ, Gough SC. Genetic developments in autoimmune thyroid disease: an evolutionary process. Clin Endocrinol. 2008;68:671–82.CrossRef
7.
go back to reference Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patient with graves’ disease treated with antithyroid agents. J Clin Invest. 1979;64:1429–36.CrossRef Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patient with graves’ disease treated with antithyroid agents. J Clin Invest. 1979;64:1429–36.CrossRef
8.
go back to reference Bliddal S, Nielsen CH, Feldt-Rasmussen U. Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Res (2017) 6: 1776. Bliddal S, Nielsen CH, Feldt-Rasmussen U. Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Res (2017) 6: 1776.
9.
go back to reference Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation. 2004;11:209–13.CrossRef Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation. 2004;11:209–13.CrossRef
10.
go back to reference Gérard AC, Boucquey M, van den Hove MF, Colin IM. Expression of TPO and ThOXs in human thyrocytes is downregulated by IL-1alpha/IFN-gamma, an effect partially mediated by nitric oxide. Am J Physiol Endocrinol Metab. 2006;291:E242–53.CrossRef Gérard AC, Boucquey M, van den Hove MF, Colin IM. Expression of TPO and ThOXs in human thyrocytes is downregulated by IL-1alpha/IFN-gamma, an effect partially mediated by nitric oxide. Am J Physiol Endocrinol Metab. 2006;291:E242–53.CrossRef
11.
go back to reference Takasu N, Yamada T, Sato A, Nakagawa M, Komiya I, Nagasawa Y, et al. Graves' disease following hypothyroidism due to Hashimoto's disease: studies of eight cases. Clin Endocrinol. 1990;33:687–98.CrossRef Takasu N, Yamada T, Sato A, Nakagawa M, Komiya I, Nagasawa Y, et al. Graves' disease following hypothyroidism due to Hashimoto's disease: studies of eight cases. Clin Endocrinol. 1990;33:687–98.CrossRef
12.
go back to reference Kamath C, Young S, Kabelis K, Sanders J, Adlan MA, Furmaniak J, et al. Thyrotropin receptor antibody characteristics in a woman with long standing Hashimoto's who developed Graves' disease and pretibial myxedema. Clin Endocrinol. 2012;77:465–70.CrossRef Kamath C, Young S, Kabelis K, Sanders J, Adlan MA, Furmaniak J, et al. Thyrotropin receptor antibody characteristics in a woman with long standing Hashimoto's who developed Graves' disease and pretibial myxedema. Clin Endocrinol. 2012;77:465–70.CrossRef
13.
go back to reference Pak S, Valencia D, Fershko A. Transformation of Hashimoto's thyroiditis to Graves' disease. Res Rev Insights. 2017;1:1–2.CrossRef Pak S, Valencia D, Fershko A. Transformation of Hashimoto's thyroiditis to Graves' disease. Res Rev Insights. 2017;1:1–2.CrossRef
14.
go back to reference Furqan S, Haque NU, Islam N. Conversion of autoimmune hypothyroidism to hyperthyroidism. BMC Res Notes. 2014;7:489.CrossRef Furqan S, Haque NU, Islam N. Conversion of autoimmune hypothyroidism to hyperthyroidism. BMC Res Notes. 2014;7:489.CrossRef
15.
go back to reference Ekpebegh C, Elmezughi K, Mtingi L. Graves' disease following hypothyroidism due to Hashimoto's thyroiditis in a black south African lady: a case report. Pan Afr Med J. 2019;32:186.CrossRef Ekpebegh C, Elmezughi K, Mtingi L. Graves' disease following hypothyroidism due to Hashimoto's thyroiditis in a black south African lady: a case report. Pan Afr Med J. 2019;32:186.CrossRef
16.
go back to reference Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, et al. Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:87–97.CrossRef Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, et al. Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:87–97.CrossRef
17.
go back to reference Burch HB, Cooper DS. Management of Graves disease: a review. JAMA. 2015;314:2544–54.CrossRef Burch HB, Cooper DS. Management of Graves disease: a review. JAMA. 2015;314:2544–54.CrossRef
18.
go back to reference Guilhem I, Massart C, Poirier JY, Maugendre D. Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal. Thyroid. 2006;16:1041–5.CrossRef Guilhem I, Massart C, Poirier JY, Maugendre D. Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal. Thyroid. 2006;16:1041–5.CrossRef
19.
go back to reference Unnikrishnan AG. Hashitoxicosis: a clinical perspective. Thyroid Res Pract. 2013;10:5–6.CrossRef Unnikrishnan AG. Hashitoxicosis: a clinical perspective. Thyroid Res Pract. 2013;10:5–6.CrossRef
Metadata
Title
Basedow’s disease with associated features of Hashimoto’s thyroiditis based on histopathological findings
Authors
Megumi Horiya
Takatoshi Anno
Fumiko Kawasaki
Yuichiro Iwamoto
Shintaro Irie
Yasumasa Monobe
Koichi Tomoda
Kohei Kaku
Shuhei Nakanishi
Hideaki Kaneto
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-00602-8

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.